Cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for potential cancer therapy: Preparation, in vitro and in vivo evaluation

Journal of Biomedical Nanotechnology

Volumn 12, Issue 1, 2016, Pages 69-78

  Yu, Haiyang ^a,d   Tang, Zhaohui ^a   Li, Mingqiang ^a,d   Song, Wantong ^a   Zhang, Dawei ^a   Zhang, Ying ^a   Yang, Yan ^b   Sun, Hai ^a   Deng, Mingxiao ^c   Chen, Xuesi ^a  

^a CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY   (China)

^b JILIN UNIVERSITY   (China)

^c NORTHEAST NORMAL UNIVERSITY   (China)

^d INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

Cancer therapy; Cisplatin; Complex; Nanoparticle; Poly(L glutamic acid)

Indexed keywords

AMINO ACIDS; BLOOD; CARDIOVASCULAR SYSTEM; DISEASES; DRUG PRODUCTS; ESTERIFICATION; ETHYLENE GLYCOL; GEL PERMEATION CHROMATOGRAPHY; MAGNETIC RESONANCE SPECTROSCOPY; METAL COMPLEXES; MOTION PICTURE EXPERTS GROUP STANDARDS; NANOPARTICLES; NUCLEAR MAGNETIC RESONANCE; ONCOLOGY; PLATINUM COMPOUNDS; POLYETHYLENE GLYCOLS; POLYOLS; TUMORS;

CANCER THERAPY; CIS-PLATIN; COMPLEX; GEL PERMEATION CHROMATOGRAPHY (GPC); METHOXYPOLYETHYLENE GLYCOL; POLY (LGLUTAMIC ACID); POLYMER-METAL COMPLEXES; STEGLICH ESTERIFICATIONS;

METAL NANOPARTICLES;

CISPLATIN; COPOLYMER; NANOPARTICLE; POLY(LEVO GLUTAMIC ACID) G METHOXY POLY(ETHYLENE GLYCOL) COMPLEX NANOPARTICLE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DELAYED RELEASE FORMULATION; MACROGOL DERIVATIVE; NANOCAPSULE; POLYGLUTAMIC ACID;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER THERAPY; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ELECTRON SPIN RESONANCE; FEMALE; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDRODYNAMICS; IN VITRO STUDY; IN VIVO STUDY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SUSTAINED DRUG RELEASE; ADMINISTRATION AND DOSAGE; ANIMAL; ANTIBODY SPECIFICITY; APOPTOSIS; BAGG ALBINO MOUSE; CELL SURVIVAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DIFFUSION; DRUG EFFECTS; FEASIBILITY STUDY; METABOLIC CLEARANCE RATE; METABOLISM; MOUSE; NEOPLASMS, EXPERIMENTAL; PARTICLE SIZE; PATHOLOGY; SYNTHESIS; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DELAYED-ACTION PREPARATIONS; DIFFUSION; FEASIBILITY STUDIES; FEMALE; HUMANS; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; NANOCAPSULES; NEOPLASMS, EXPERIMENTAL; ORGAN SPECIFICITY; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYGLUTAMIC ACID; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 84960089137     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2016.2152     Document Type: Article

References (41)

1. R. Gref, Y. Minamitake, M. T. Peracchia, V. Trubetskoy, V. Torchilin, and R. Langer, Biodegradable long-circulating polymeric nanospheres. Science 263, 1600 (1994).
2. Z. L. Tyrrell, Y. Shen, and M. Radosz, Fabrication of micellar nanoparticles for drug delivery through the self-assembly of block copolymers. Prog. Polym. Sci. 35, 1128 (2010).
3. K. Wang, G. F. Luo, Y. Liu, C. Li, S. X. Cheng, R. X. Zhuo, and X. Z. Zhang, Redox-sensitive shell cross-linked PEG-polypeptide hybrid micelles for controlled drug release. Polym. Chem.-UK 3, 1084 (2012).
4. C.-Y. Long, M.-M. Sheng, B. He, Y. Wu, G. Wang, and Z.-W. Gu, Comparison of drug delivery properties of PEG-b-pdhpc micelles with different compositions. Chin. J. Polym. Sci. 30, 387 (2012).
5. V. A. Sethuraman and Y. H. Bae, TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J. Control. Release 118, 216 (2007).
6. Z. X. Zhou, Y. Q. Shen, J. B. Tang, M. H. Fan, E. A. Van Kirk, W. J. Murdoch, and M. Radosz, Charge-reversal drug conjugate for targeted cancer cell nuclear drug delivery. Adv. Funct. Mater. 19, 3580 (2009).
7. J. Z. Du, T. M. Sun, W. J. Song, J. Wu, and J. Wang, A tumoracidity-activated charge-conversional nanogel as an intelligent vehicle for promoted tumoral-cell uptake and drug delivery. Angew. Chem. Int. Edit. 49, 3621 (2010).
8. D. Peer, J. M. Karp, S. Hong, O. C. FaroKHzad, R. Margalit, and R. Langer, Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751 (2007).
9. K. J. Lee, J. H. An, J. R. Chun, K. H. Chung, W. Y. Park, J. S. Shin, D. H. Kim, and Y. Y. Bahk, In vitro analysis of the anticancer activity of mitoxantrone loaded on magnetic nanoparticles. J. Biomed. Nanotechnol. 9, 1071 (2013).
10. G. Zhang, X. Zeng, and P. Li, Nanomaterials in cancer-therapy drug delivery system. J. Biomed. Nanotechnol. 9, 741 (2013).
11. F. Danhier, O. Feron, and V. Preat, To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release 148, 135 (2010).
12. Y. Matsumura and K. Kataoka, Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci. 100, 572 (2009).
13. A. Gabizon, R. Catane, B. Uziely, B. Kaufman, T. Safra, R. Cohen, F. Martin, A. Huang, and Y. Barenholz, Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54, 987 (1994).
14. N. Desai, V. Trieu, Z. W. Yao, L. Louie, S. Ci, A. Yang, C. L. Tao, T. De, B. Beals, D. Dykes, P. Noker, R. Yao, E. Labao, M. Hawkins, and P. Soon-Shiong, Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res. 12, 1317 (2006).
15. S. C. Kim, D. W. Kim, Y. H. Shim, J. S. Bang, H. S. Oh, S. W. Kim, and M. H. Seo, In vivo evaluation of polymeric micellar paclitaxel formulation: Toxicity and efficacy. J. Control. Release 72, 191 (2001).
16. S. Taurin, H. Nehoff, and K. Greish, Anticancer nanomedicine and tumor vascular permeability; Where is the missing link? J. Control. Release 164, 265 (2012).
17. L. Kelland, The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 7, 573 (2007).
18. S. Dhar, N. Kolishetti, S. J. Lippard, and O. C. Farokhzad, Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. P. Natl. Acad. Sci. USA 108, 1850 (2011).
19. M. Galanski, M. A. Jakupec, and B. K. Keppler, Update of the preclinical situation of anticancer platinum complexes: Novel design strategies and innovative analytical approaches. Curr Med. Chem. 12, 2075 (2005).
20. N. E. Madias and J. T. Harrington, Platinum nephrotoxicity. Am. J. Med. 65, 307 (1978).
21. N. Nishiyama, S. Okazaki, H. Cabral, M. Miyamoto, Y. Kato, Y. Sugiyama, K. Nishio, Y. Matsumura, and K. Kataoka, Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res. 63, 8977 (2003).
22. N. Nishiyama, M. Yokoyama, T. Aoyagi, T. Okano, Y. Sakurai, and K. Kataoka, Preparation and characterization of self-assembled polymer-Metal complex micelle from cis-dichlorodiammineplatinum (II) and poly (ethylene glycol)-Poly (α, β-aspartic acid) block copolymer in an aqueous medium. Langmuir 15, 377 (1999).
23. Y. Xiong, W. Jiang, Y. Shen, H. Li, C. Sun, A. Ouahab, and J. Tu, A poly (γ, l-glutamic acid)-citric acid based nanoconjugate for cisplatin delivery. Biomaterials 33, 7182 (2012).
24. M. Yokoyama, T. Okano, Y. Sakurai, S. Suwa, and K. Kataoka, Introduction of cisplatin into polymeric micelle. J. Control. Release 39, 351 (1996).
25. K. Avgoustakis, A. Beletsi, Z. Panagi, P. Klepetsanis, A. G. Karydas, and D. S. Ithakissios, PLGA-mPEG nanoparticles of cisplatin: In vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J. Control. Release 79, 123 (2002).
26. G. Mattheolabakis, E. Taoufik, S. Haralambous, M. L. Roberts, and K. Avgoustakis, In vivo investigation of tolerance and antitumor activity of cisplatin-loaded PLGA-mPEG nanoparticles. Eur. J. Pharm. Biopharm. 71, 190 (2009).
27. H. Uchino, Y. Matsumura, T. Negishi, F. Koizumi, T. Hayashi, T. Honda, N. Nishiyama, K. Kataoka, S. Naito, and T. Kakizoe, Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Brit. J. Cancer 93, 678 (2005).
28. S. Dhar, F. X. Gu, R. Langer, O. C. Farokhzad, and S. J. Lippard, Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt (IV) prodrug-PLGA-PEG nanoparticles. P. Natl. Acad. Sci. USA 105, 17356 (2008).
29. A. S. Paraskar, S. Soni, K. T. Chin, P. Chaudhuri, K. W. Muto, J. Berkowitz, M. W. Handlogten, N. J. Alves, B. Bilgicer, D. M. Dinulescu, R. A. Mashelkar, and S. Sengupta, Harnessing structureactivity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy. P. Natl. Acad. Sci. USA 107, 12435 (2010).
30. Y. Zou, L. Wang, and X. Liu, Poly (ethylene glycol) activation and its application as carrier in drug delivery and as support in organic synthesis. World Sci.-Tech. R and D 25, 63 (2003).
31. B. Neises and W. Steglich, Simple method for the esterification of carboxylic acids. Angewandte Chemie International Edition in English 17, 522 (1978).
32. W. Song, M. Li, Z. Tang, Q. Li, Y. Yang, H. Liu, T. Duan, H. Hong, and X. Chen, Methoxypoly (ethylene glycol)-block-poly (L-glutamic acid)-loaded cisplatin and a combination with iRGD for the treatment of non-small-cell lung cancers. Macromol. Biosci. 12, 1514 (2012).
33. W. T. Song, M. Q. Li, Z. H. Tang, Q. S. Li, Y. Yang, H. Y. Liu, T. C. Duan, H. Hong, and X. S. Chen, Methoxypoly (ethylene glycol) - block-poly (L-glutamic acid)-loaded cisplatin and a combination with iRGD for the treatment of non-small-cell lung cancers. Macromolecular Bioscience 12, 1514 (2012).
34. L. Zhao, J. Ding, C. Xiao, P. He, Z. Tang, X. Pang, X. Zhuang, and X. Chen, Glucose-sensitive polypeptide micelles for self-regulated insulin release at physiological pH. J. Mater. Chem. (2012).
35. N. Nishiyama and K. Kataoka, Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacology and Therapeutics 112, 630 (2006).
36. X. Duan and Y. Li, Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking. Small 9, 1521 (2013).
37. R. Trivedi and U. B. Kompella, Nanomicellar formulations for sustained drug delivery: Strategies and underlying principles. Nanomedicine-UK 5, 485 (2010).
38. X. Zhao, Z. Poon, A. C. Engler, D. K. Bonner, and P. T. Hammond, Enhanced stability of polymeric micelles based on postfunctionalized poly (ethylene glycol)-b-poly (γ-propargyl L-glutamate): The substituent effect. Biomacromolecules 13, 1315 (2012).
39. L. Z. Zhang, Y. J. Zhang, W. Wu, and X. Q. Jiang, Doxorubicin-loaded boron-rich polymer nanoparticles for orthotopically implanted liver tumor treatment. Chin. J. Polym. Sci. 31, 778 (2013).
40. C. M. Gillen, A. Takamata, G. W. Mack, and E. R. Nadel, Measurement of plasma volume in rats with use of fluorescent-labeled albumin molecules. Journal of Applied Physiology 76, 485 (1994).
41. L. M. Kaminskas, V. M. McLeod, B. D. Kelly, G. Sberna, B. J. Boyd, M. Williamson, D. J. Owen, and C. J. H. Porter, A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems. Nanomed.-Nanotechnol. 8, 103 (2012).